Multiple sclerosis, rituximab, and COVID-19
| Autor: | Annette, Langer-Gould, Jessica B, Smith, Bonnie H, Li, Oluwasheyi, Ayeni |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Multiple Sclerosis Coronavirus disease 2019 (COVID-19) Population Neurosciences. Biological psychiatry. Neuropsychiatry Brief Communication Cohort Studies 03 medical and health sciences 0302 clinical medicine Internal medicine Epidemiology medicine Humans Immunologic Factors Dosing education RC346-429 Infusions Intravenous Retrospective Studies education.field_of_study business.industry General Neuroscience Multiple sclerosis COVID-19 Retrospective cohort study Middle Aged medicine.disease Hospitalization 030104 developmental biology Rituximab Female Neurology (clinical) Neurology. Diseases of the nervous system business Brief Communications 030217 neurology & neurosurgery medicine.drug Cohort study RC321-571 |
| Zdroj: | Annals of Clinical and Translational Neurology Annals of Clinical and Translational Neurology, Vol 8, Iss 4, Pp 938-943 (2021) |
| ISSN: | 2328-9503 |
| Popis: | We conducted a retrospective cohort study in Kaiser Permanente Southern California from 1 January 2020 to 30 September 2020. We found that rituximab‐treated persons with multiple sclerosis (pwMS, n = 1895) were more likely be hospitalized (n = 8, 33.3%), but not die (n = 0) from COVID‐19, compared to the 4.81 million non‐MS population (5.8% and 1.4%, respectively). Time in months (adjusted OR = 0.32, 95% CI = 0.15–0.69, p = 0.0033) and receiving 1000 mg compared to lower doses at last infusion (adjusted OR = 6.28, 95% CI = 1.38–28.5, p = 0.0173) were independent predictors of COVID‐19 severity. Rituximab‐treated pwMS should be counseled to take extra precautions in the 5 months following each infusion. Using extended dosing intervals and lower doses could be considered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|